((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
Overview
* U.S. proteomics technology provider's Q2 revenue fell 23% yr/yr due to macroeconomic headwinds
* Net loss for Q2 narrowed as operating expenses declined 19% yr/yr
* Company repurchased about 200,000 shares under its share repurchase program
Outlook
* Seer maintains 2026 revenue guidance of $16 mln to $18 mln
Result Drivers
* MACROECONOMIC HEADWINDS - Co said lower product and service revenue was primarily due to continued macroeconomic headwinds in academic and government funding
* LONGER SALES CYCLES - Co cited continued elongation of sales cycles in some commercial accounts related to extended customer evaluations
* LOWER OPERATING EXPENSES - Operating expenses fell mainly due to a decrease in employee compensation expenses, including stock-based compensation
Company press release: ID:nGNX7MDKMb
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q2 $3.10
Revenue mln
Q2 Loss $0.31
Per
Share
Q2 Net $16.90
Loss mln
Q2 Gross 49%
Margin
Q2 Gross $1.51
Profit mln
Q2 $18.35
Operatin mln
g
Expenses
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the office equipment peer group is "buy"
* Wall Street's median 12-month price target for Seer, Inc. is $4.00, about 85.2% above its August 10 closing price of $2.16
Reuters Recommended Reads
* Aug 10 - Bionano Genomics Q2 revenue rises on increased clinical adoption
* Aug 11 - 908 Devices Q2 revenue beats on increased VipIR sales
* Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)